Related Experiment Videos

Hickman catheter complications in a haematology unit, 1996-98

R A Soo¹, I B Gosbell, J H Gallo

¹Department of Haematology and Oncology, National University Hospital, Singapore.

Internal Medicine Journal

|March 12, 2002

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small-cell lung cancer: 7-year update from the phase III CROWN study.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance - The ETOP 15-19 ABC-lung trial.

Lung cancer (Amsterdam, Netherlands)·2025

The value of disease-free survival (DFS) and osimertinib in adjuvant non-small-cell lung cancer (NSCLC): an international Delphi consensus report.

ESMO open·2022

Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis.

ESMO open·2022

A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2021

Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS.

Annals of oncology : official journal of the European Society for Medical Oncology·2019

See all related articles